# Pizarra — PT-pseudo_562159dc2cc6 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.43 +/- 0.23   (95% CI 0.06-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.21  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 2.5 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=2.0, bx_ord=0.0, psa=9.9, age=48.0, psad=0.19, dre_ord=0.0, vol=50.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: DEFER BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=2, PSA=9.9, csPCa probability=0.6607788, DRE=Normal) and could not weigh the patient's history of fluctuating PSA values (first documented at 9.3 ng/mL in early 2024) or the specific PSA velocity (0.31 ng/mL/yr).
The prior did not account for the clinical context of moderate LUTS (IPSS 15/35) or the patient's lifestyle factors (ex-smoker, hiking).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested "NO BIOPSY" with a wide uncertainty interval (0.43 +/- 0.23), indicating the classifier is genuinely unable to distinguish between biopsy and no biopsy. This wide interval suggests the statistical model is highly uncertain for this specific profile.
The protocol expert deferred biopsy based solely on PI-RADS 2, but this ignores the rising PSA (from 6.7 to 9.9 ng/mL) and the clinical suspicion indicated by the high csPCa probability (0.6607788).
The prior's reliance on the visible panel is insufficient because it fails to integrate the PSA trajectory, which is a critical dynamic factor.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding fluctuating PSA values
laboratory panel - full panel
family-history of prostate cancer (anamnesis)

GUIDELINE ANCHOR
The guideline states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, and deferral is recommended when PI-RADS is 1-2. This constrains the decision based on the current PI-RADS score of 2.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_562159dc2cc6", "radiology_report": "Subject: Prostate MRI | Spaarne Gasthuis, Haarlem | 20 January 2025\nClinical Query: Persistent PSA elevation (9.9 ng/mL) and prior scoring.\nFINDINGS:\nVolumetric assessment yields a gland size of 50.0 mL. T2-weighted sequences reveal a homogeneous peripheral zone, lacking focal signal drops or diffusion restriction on ADC maps. Mild nodular hyperplasia characterizes the transition zone, aligning with benign enlargement. Dynamic contrast phases exhibit no early or focal enhancement patterns. Seminal vesicles maintain normal caliber and signal intensity. There is no evidence of extraprostatic spread or suspicious nodal disease.\nIMPRESSION:\nBenign prostatic enlargement measuring 50.0 mL. No PI-RADS 3 or higher lesion identified. PI-RADS 2.\nPSA density: 0.19 ng/mL/mL.\ncsPCa predicted probability 0.6607788."}
get_psa_trend
{"case_id": "PT-pseudo_5622159dc2cc6", "psa_trend": [{"date": "Feb 2024", "val": 2.9}, {"date": "Aug 2024", "val": 4.9}, {"date": "Jan 2025", "val": 9.9}]}
get_previous_notes
{"case_id": "PT-pseudo_562159dc2cc6", "previous_notes": [{"date": "03 Feb 2024", "author": "Dr. R. Visser (GP)", "text": "Initial laboratory screening in February 2024 flagged a PSA reading of 9.3 ng/mL, which triggered a repeat draw and urology referral. Follow-up values temporarily decreased to 6.7 ng/mL during August, before climbing back to 9.9 ng/mL. The most recent multiparametric MRI scans and updated chemistry panel have been dispatched for specialist assessment."}]}
get_lab_results
{"case_id": "PT-pseudo_562159dc2cc6", "laboratory_results": [{"name": "PSA", "val": "9.9 ng/mL", "date": "28 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.76 ng/mL", "date": "28 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "28%", "date": "28 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "14.6 g/dL", "date": "28 Dec 2024", "flag": ""}, {"name": "WBC", "val": "4.7 x10^9/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "263 x10^9/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "92 umol/L", "date": "28 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "28 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "17.2 nmol/L", "date": "28 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "71 U/L", "date": "28 Dec 2024", "flag": ""}, {"name": "LDH", "val": "245 U/L", "date": "28 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.8 %", "date": "28 Dec 2024", "flag": ""}]}
NOT RETRIEVED
The pathology report was not retrieved because the case file indicated no prior biopsy was on record.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity of 0.31 ng/mL/yr, indicating a rising trend from 6.7 ng/mL to 9.9 ng/mL.
- csPCa predicted probability of 0.6607788, suggesting significant clinical suspicion.
AGAINST sampling this patient now:
- mpMRI PI-RADS score of 2, which falls into the deferral range according to the protocol.
- DRE findings are Normal.
WHERE THIS LEANS
The rising PSA trend and high predicted probability argue for further investigation despite the PI-RADS 2 score, suggesting a lean towards considering biopsy to clarify the rising trend.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The guideline criterion dictates deferral because the mpMRI showed a PI-RADS 2, which falls into the deferral range. Although the PSA velocity was rising (0.31 ng/mL/yr) and the csPCa probability was high (0.66), the retrieved radiology report explicitly stated 'No PI-RADS 3 or higher lesion identified.' This finding, combined with the PI-RADS 2 score, overrides the clinical suspicion for immediate biopsy.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
